We and others have demonstrated that Gal-3 inhibition improves cardiovascular remodeling in several pathological conditions such as hyperaldosteronism, obesity, hypertension, angiotensin II treatment, pressure overload and aortic stenosis5–8. Here, LGALS3 is linked to obesity due to melanocortin 4 receptor deficiency.